Neurocrine Biosciences Inc (NBIX) - Total Assets
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) holds total assets worth $4.63 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Neurocrine Biosciences Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Neurocrine Biosciences Inc - Total Assets Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Explore NBIX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Neurocrine Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Neurocrine Biosciences Inc's total assets of $4.63 Billion consist of 54.5% current assets and 45.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.4% |
| Accounts Receivable | $686.80 Million | 14.8% |
| Inventory | $69.00 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NBIX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurocrine Biosciences Inc's current assets represent 54.5% of total assets in 2025, a decrease from 92.4% in 1996.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2025, up from 14.5% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 14.8% of total assets.
Neurocrine Biosciences Inc Competitors by Total Assets
Key competitors of Neurocrine Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
IPSEN SA SP.ADR 1/4/ EO 1
F:I7G0
|
Germany | €6.94 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Neurocrine Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.39 | 3.40 | 5.71 |
| Quick Ratio | 3.30 | 3.28 | 5.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.78 Billion | $1.22 Billion | $895.40 Million |
Neurocrine Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Neurocrine Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.94 |
| Latest Market Cap to Assets Ratio | 2.81 |
| Asset Growth Rate (YoY) | 24.5% |
| Total Assets | $4.63 Billion |
| Market Capitalization | $13.03 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurocrine Biosciences Inc's assets at a significant premium (2.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neurocrine Biosciences Inc's assets grew by 24.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual total assets of Neurocrine Biosciences Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $4.63 Billion | +24.55% |
| 2024-12-31 | $3.72 Billion | +14.37% |
| 2023-12-31 | $3.25 Billion | +37.27% |
| 2022-12-31 | $2.37 Billion | +14.29% |
| 2021-12-31 | $2.07 Billion | +19.47% |
| 2020-12-31 | $1.73 Billion | +32.83% |
| 2019-12-31 | $1.31 Billion | +31.50% |
| 2018-12-31 | $993.15 Million | +21.47% |
| 2017-12-31 | $817.59 Million | +123.94% |
| 2016-12-31 | $365.09 Million | -23.10% |
| 2015-12-31 | $474.79 Million | +95.36% |
| 2014-12-31 | $243.03 Million | +57.12% |
| 2013-12-31 | $154.68 Million | -21.08% |
| 2012-12-31 | $195.98 Million | +41.64% |
| 2011-12-31 | $138.37 Million | -4.19% |
| 2010-12-31 | $144.42 Million | +103.94% |
| 2009-12-31 | $70.82 Million | -40.08% |
| 2008-12-31 | $118.18 Million | -57.28% |
| 2007-12-31 | $276.65 Million | -29.00% |
| 2006-12-31 | $389.68 Million | -19.34% |
| 2005-12-31 | $483.12 Million | -6.95% |
| 2004-12-31 | $519.22 Million | -6.44% |
| 2003-12-31 | $554.96 Million | +108.21% |
| 2002-12-31 | $266.54 Million | -23.04% |
| 2001-12-31 | $346.35 Million | +86.25% |
| 2000-12-31 | $185.96 Million | +70.29% |
| 1999-12-31 | $109.20 Million | +35.65% |
| 1998-12-31 | $80.50 Million | -12.40% |
| 1997-12-31 | $91.90 Million | +17.82% |
| 1996-12-31 | $78.00 Million | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more